Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 12

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 12
---
 for drugs in development and in subsequent clinical practice. As Renovaro Cube collects more data, longitudinal about treatment and response, 
 it will have the ability to train prognostic models to give an insight in disease progression and treatment response, both critical for       
 enrolling in clinical trials and eventually every treatment. Because Renovaro Cube consists of many independently trained and validated       
 models, it will have the ability to assist in virtually every therapeutic decision, for different subtypes and groups (stratifications).      
 The multi-omics and multi-modal pipelines could allow the use of multiple combinations of tissue samples and diagnostic platforms. The        
 detailed diagnostic reports will allow and support insights for multiple disciplines such as cancer biology, genomics and pathology to        
 look at underpinning biomarkers, pathways and clinical annotations.                                                                           |

| · | Provides insight into patients who have had cancer previously. These insights will provide for more effective                                  
 recurrence monitoring, which Renovaro Cube believes is important to the providers of care and patients during follow-up monitoring of          
 remissions. Renovaro Cube anticipates that payers want to detect and re-treat recurrences at the earliest possible stage to maximize patients’ 
 outcomes in terms of time and cost and that, similarly, patients with a recurrence are keen to re-engage with effective treatment at the       
 earliest opportunity. A key aspect of this will be taking blood from the patients, sequencing this blood and running it through the Renovaro   
 Cube platform which will identify if the patient has any indication of the recurrence of the same or a new cancer. For recurrence monitoring,  
 Renovaro Cube will focus on a highly sensitive combination of lab and information technology. Lab protocols, sequence post processing          
 and machine learning are all designed, trained and validated to get the best signal with the highest sensitivity to catch early signals        
 of recurrence. This will be done on a regular basis allowing surveillance analysis over time.                                                  |

| · | Includes biomarker panels that will be extended to include as many layers of genetic information (multi-omics) as possible including mutation, gene expression, methylation status, fragmentomics, nucleosome mapping, collectively named multi-omics, with the goal to reach the highest accuracy possible, both in terms of sensitivity and specificity of each individual biomarker panel. This provides a non-invasive alternative for the current complex, expensive and cumbersome procedures. |

| ● | Create value through advancing more sophisticated typification of diseases in an effort to address some of the pressing problems faced by modern healthcare, including healthcare costs